$LMWHs have additional advantage over unfractionated heparin: no volume load$

LMWHs have additional advantage over unfractionated heparin: no volume load

Bibliographic Details
Main Author:	GP Koracevic
Format:	Article
Language:	English
Published:	SMW supporting association (Trägerverein Swiss Medical Weekly SMW) 2009-10-01
Series:	Swiss Medical Weekly
Subjects:	renal failure heart failure Unfractionated heparin LMWH
Online Access:	https://www.smw.ch/index.php/smw/article/view/1039

Similar Items

Therapeutic inefficacy of protocol driven intravenous unfractionated heparin infusion in the current era
by: Kayla Torppey, et al.
Published: (2023-10-01)

Comparison of Two Nomograms of Unfractionated Heparin in Patients with Acute Coronary Syndrome
by: Moneyreh Modares Mosadegh, et al.
Published: (2013-02-01)

Comparison of Two Nomograms of Unfractionated Heparin in Patients with Acute Coronary Syndrome
by: Moneyreh Modares Mosadegh, et al.
Published: (2013-02-01)

Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis
by: Hind Harrak Lazrak, et al.
Published: (2017-06-01)

Comparison of Pregnancy Outcomes of Low Molecular Weight Heparin with Unfractionated Heparin in the Treatment of Recurrent Abortion Secondary to Antiphospholipid Syndrome
by: M Janghorbani, et al.
Published: (2013-09-01)

Randomized, Blinded Trial Comparing Enoxaparin with Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention
by: Hosein Vakili, et al.
Published: (2007-04-01)

Randomized, Blinded Trial Comparing Enoxaparin with Unfractionated Heparin in Patients Undergoing Contemporary Percutaneous Coronary Intervention
by: Hosein Vakili, et al.
Published: (2007-07-01)

Effectiveness, safety, and costs of thromboprophylaxis with enoxaparin or unfractionated heparin in inpatients with obesity
by: Alpesh Amin, et al.
Published: (2023-06-01)

Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement
by: Benjamin Lardinois, et al.
Published: (2022-02-01)

Unfractionated heparin improves the clinical efficacy in adult sepsis patients: a systematic review and meta-analysis
by: Sifeng Fu, et al.
Published: (2022-01-01)

Pregnancy outcome in women with mechanical prosthetic heart valvesat their first trimester of pregnancy treated with unfractionated heparin (UFH) or enoxaparin: A randomized clinical trial
by: Minoo Movahedi, et al.
Published: (2020-09-01)

Low molecular weight heparin versus Unfractionated heparin in patients with non ST-elevation acute coronary syndrome: a randomaized clinical trial
by: Zand parsa A, et al.
Published: (2007-09-01)

Low-molecular-weight heparin in patients with renal insufficiency
by: AG Fischer
Published: (2009-08-01)

Osteoporotic fracture rates in chronic hemodialysis and effect of heparin exposure: a retrospective cohort study
by: Hind Harrak, et al.
Published: (2020-07-01)

Thrombolysis versus unfractionated heparin for hemodynamically stable patients with pulmonary embolism: a systematic review and meta-analysis
by: N. A. Cherepanova, et al.
Published: (2022-09-01)

Delayed prophylaxis with unfractionated heparin increases the risk of venous thromboembolic events in patients with moderate to severe traumatic brain injury: a retrospective analysis
by: Giovanna Brandi, et al.
Published: (2020-03-01)

The use of activated partial thromboplastin time versus antifactor Xa assay in monitoring continuous unfractionated heparin infusion therapy in obstetric intensive care unit
by: Hany V. Zaki, et al.
Published: (2019-02-01)

Unfractionated heparin ameliorates pulmonary microvascular endothelial barrier dysfunction via microtubule stabilization in acute lung injury
by: Shengtian Mu, et al.
Published: (2018-11-01)

Enoxaparin versus Unfractionated Heparin for the Perioperative Anticoagulant Therapy in Patients with Mechanical Prosthetic Heart Valve Undergoing Non-Cardiac Surgery
by: Luminita Iliuta, et al.
Published: (2022-08-01)

Laboratory Assessment of Unfractionated Heparin (UFH) with Activated Clotting Time (ACT) and Anti-Xa Activity during Peripheral Arterial Angiographic Procedure
by: Tuukka Helin, et al.
Published: (2023-04-01)

Immunological effects of anti-coagulant unfractionated heparin in pregnant Chinese women with cryptic recurrent miscarriages
by: Yanli Hong, et al.
Published: (2020-06-01)

Heparin‐induced hyperkalemia, can LMWH cause hyperkalemia? A systematic review
by: Gedion Yilma Amdetsion, et al.
Published: (2023-11-01)

The Antineoplastic Effect of Heparin on Colorectal Cancer: A Review of the Literature
by: Emmanuel Giannas, et al.
Published: (2023-11-01)

Inactivation of Heparin by Cationically Modified Chitosan
by: Barbara Lorkowska-Zawicka, et al.
Published: (2014-06-01)

Low-Dose Unfractionated Heparin with Sequential Enoxaparin in Patients with Diabetes Mellitus and Complex Coronary Artery Disease during Elective Percutaneous Coronary Intervention
by: Ji Huang, et al.
Published: (2018-01-01)

Does ‘heparin-induced thrombocytopenia’ hit our minds?
by: Arun R. Thangavel, et al.
Published: (2016-08-01)

Standard dosing of enoxaparin versus unfractionated heparin in critically ill patient with COVID-19: a multicenter propensity-score matched study
by: Khalid Al Sulaiman, et al.
Published: (2022-12-01)

Incidence of anti-heparin/platelet factor 4 antibodies and heparin-induced thrombocytopenia in medical patients
by: Mahmut Yüksel, et al.
Published: (2009-12-01)

Unfractionated heparin versus nafamostat mesylate for anticoagulation during continuous kidney replacement therapy: an observational study
by: Shinya Kameda, et al.
Published: (2023-01-01)

Protective Effect of Unfractionated Heparin on Lipopolysaccharide-Induced Acute Respiratory Distress Syndrome in Neonatal Mice via the JAK2/STAT3 Signaling Pathway
by: Jing Xiong, et al.
Published: (2023-06-01)

Pharmacokinetic, Hemostatic, and Anticancer Properties of a Low-Anticoagulant Bovine Heparin
by: Roberto P. Santos, et al.
Published: (2022-04-01)

New Insights in Thrombin Inhibition Structure–Activity Relationships by Characterization of Octadecasaccharides from Low Molecular Weight Heparin
by: Pierre A. J. Mourier, et al.
Published: (2017-03-01)

Preliminary Experience With Low Molecular Weight Heparin Strategy in COVID-19 Patients
by: Pasquale Paolisso, et al.
Published: (2020-08-01)

Un‐fractionated heparin counteracts the systemic inflammatory responses and multiple organ damages caused by endotoxaemia in sheep
by: Hesam Ashareyoun, et al.
Published: (2022-05-01)

Heparin: The Silver Bullet of Aneurysmal Subarachnoid Hemorrhage?
by: Nicolas K. Khattar, et al.
Published: (2018-03-01)

Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence
by: Frank M. P. van Haren, et al.
Published: (2020-07-01)

Ewolucja leczenia przeciwzakrzepowego – od kleszcza i pijawki do tabletki
by: Wiesława Bednarek, et al.
Published: (2010-08-01)

Heparins Sourced From Bovine and Porcine Mucosa Gain Exclusive Monographs in the Brazilian Pharmacopeia
by: Eduardo Vilanova, et al.
Published: (2019-02-01)

The Challenge of Hemorrhagic Shock Management During Low-Molecular-Weight Heparin Treatment
by: Morotti A, et al.
Published: (2020-03-01)

Pilot study examining anti-factor Xa levels for heparin monitoring and outcomes in patients with cerebral venous thrombosis
by: Yasaman Pirahanchi, et al.
Published: (2024-01-01)